Form 4: Foghorn Therapeutics Director Douglas Cole Granted 25,000 Stock Options

Foghorn Therapeutics Inc. Director Douglas G. Cole was granted 25,000 stock options at an exercise price of $4.79, aligning his interests with shareholder value.

Summary

• Douglas G. Cole, a Director of Foghorn Therapeutics Inc. (FHTX), acquired 25,000 stock options on June 17, 2025.
• The acquired stock options have an exercise price of $4.79 per share.
• These options will become exercisable on June 17, 2026, and are set to expire on June 16, 2035.
• Following this transaction, Mr. Cole directly beneficially owns 25,000 derivative securities.
• The filing also includes a Limited Power of Attorney, dated March 19, 2025, authorizing Kristian Humer and Michael LaCascia to file SEC reports on behalf of Mr. Cole.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is generally viewed as a neutral to slightly positive event, as it aligns the director's financial interests with the company's long-term stock performance, without indicating any immediate operational or financial changes.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance and value creation.
• The transaction represents a standard compensation practice aimed at retaining and motivating key personnel.

Future Outlook

This document, a Form 4, does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports an insider transaction.

Management Comments

• "The undersigned acknowledges that each foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended."

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction within the biotechnology/pharmaceutical industry, where stock options are a common component of executive and director compensation packages to align interests with company performance.

Comparison to Industry Standards

• The granting of stock options to directors is a standard practice in publicly traded companies, particularly in growth-oriented sectors like biotechnology, to incentivize long-term value creation. Specific comparable companies or projects are not detailed in this filing, as it focuses on an individual's transaction.

Corporate Governance

Related Party Transactions

• The stock option grant is an insider transaction, which is a form of related party dealing between the company and its director as part of compensation.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can be seen as a positive for shareholders, as it aligns the director's financial interests with the company's long-term stock performance.

Next Steps

• The acquired stock options will become exercisable on June 17, 2026.
• The options will expire on June 16, 2035, unless exercised prior.

Key Dates

Keywords

SEC Form 4, Foghorn Therapeutics, FHTX, Stock Options, Insider Transaction, Director Compensation, Douglas G. Cole, Biotechnology